• / Free eNewsletters & Magazine
  • / My Account

AES

The AES Corporation AES 3 Star

Last Price$13.50Day Change (%)2.20%
Open Price$13.25Day Change ($)0.29
Day Range13.23–13.6052-Week Range12.38–15.65

As of Fri 12/19/2014 07:06 PM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Fitch Affirms AES and the U.S. Units; Outlook Negative for AES

    Fitch Affirms AES and the U.S. Units; Outlook Negative for AES

  2. UPDATE: Boeing's shares get lift from dividend hike, buyback

    UPDATE: Boeing's shares get lift from dividend hike, buyback

  3. UPDATE: PetSmart rallies on takeover talk; Ford gets downgraded

    UPDATE: PetSmart rallies on takeover talk; Ford gets downgraded

  4. UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES )

    UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society ( AES )

  5. Research and Markets: Thermal Power in Billion Kilowatt-hours by Gas, Oil, and Coal - 2014 Global Strategic Business Report

    Research and Markets: Thermal Power in Billion Kilowatt-hours by Gas, Oil, and Coal - 2014 Global Strategic Business Report

  6. Microsemi's Ultra-secure SmartFusion2 SoC FPGAs and IGLOO2 FPGAs Recognized on EDN's List of Hot 100 Products of 2014

    Microsemi's Ultra-secure SmartFusion2 SoC FPGAs and IGLOO2 FPGAs Recognized on EDN's List of Hot 100 Products of 2014

  7. Research and Markets: Food Safety Testing: Pathogens Testing, Pesticide Testing, GMO Testing & Other Testing - 2014 Global Strategic Business Report

    Research and Markets: Food Safety Testing: Pathogens Testing, Pesticide Testing, GMO Testing & Other Testing - 2014 Global Strategic Business Report

  8. Fitch: Latin American Leveraged Finance Credits Conditions Drive Negative Trends

    Fitch: Latin American Leveraged Finance Credits Conditions Drive Negative Trends

  9. /C O R R E C T I O N -- Cellcrypt/

    /C O R R E C T I O N -- Cellcrypt/

  10. Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma

    Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.